Comparative Pharmacology
Head-to-head clinical analysis: CIN QUIN versus QUINIDINE GLUCONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIN QUIN versus QUINIDINE GLUCONATE.
CIN-QUIN vs QUINIDINE GLUCONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Class Ia antiarrhythmic agent; blocks sodium channels (Nav1.5) and potassium channels (IKr, IKs), prolongs action potential duration and effective refractory period; also has anticholinergic and alpha-adrenergic blocking effects.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
324-648 mg orally every 8-12 hours; maximum 3.24 g/day. Also administered IV as quinidine gluconate 200-400 mg (diluted) at a rate ≤1 mL/min.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Terminal elimination half-life: 6-8 hours (range 4-12 hours) in healthy adults; prolonged in HF, renal impairment, or elderly.
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
Renal: 50-70% unchanged; Biliary/fecal: 20-30%; Hepatic metabolism accounts for 10-30%.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)